Share on StockTwits

Lumenis (NASDAQ:LMNS)‘s stock had its “outperform” rating reiterated by stock analysts at Credit Suisse in a report issued on Tuesday, Analyst Ratings Network reports. They currently have a $14.00 price objective on the stock. Credit Suisse’s price target suggests a potential upside of 40.56% from the company’s current price.

Separately, analysts at Goldman Sachs reiterated a “buy” rating on shares of Lumenis in a research note on Tuesday. They now have a $17.00 price target on the stock.

Lumenis (NASDAQ:LMNS) opened at 9.96 on Tuesday. Lumenis has a one year low of $9.77 and a one year high of $13.38. The stock’s 50-day moving average is $11.73 and its 200-day moving average is $11.73. The company has a market cap of $350.9 million and a P/E ratio of 18.48.

Lumenis Ltd. is a provider of energy-based, minimally invasive clinical solutions. The Company operated in three segments: surgical, ophthalmic and aesthetic.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.